HANSOH PHARMA (03692) and GLENMARK enter into a licensing agreement for Ameinib

Hansoh Pharma (03692) announced that on December 16, 2025, its wholly-owned subsidiary Jiangsu Haosen Pharmaceutical Group Co., Ltd. (licensor) entered into an exclusive license, collaboration, and distribution agreement with Glenmark Specialty S.A. (licensee) for the drug Amevatinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) used to treat non-small cell lung cancer (NSCLC). Under the license agreement, the licensor will grant the licensee exclusive rights to develop and commercialize Amevatinib in the authorized territories (Middle East and Africa, Southeast Asia and South Asia, Australia, New Zealand, Russia and other CIS countries, as well as specific Caribbean countries covered by the agreement). The licensor will receive upfront and potential cumulative regulatory and commercial milestone payments totaling over one billion US dollars, as well as tiered royalty payments based on net sales in the authorized territories.